Cover Image
市場調查報告書

副甲狀腺功能低下症:開發平台分析

Hypoparathyroidism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200460
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
副甲狀腺功能低下症:開發平台分析 Hypoparathyroidism - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 51 Pages
簡介

副甲狀腺功能低下症是副甲狀腺功能低落造成副甲狀腺激素產量降低,伴隨有血中鈣濃度低,肌肉痙攣和收縮(不隨便肌收縮),及其他症狀。雖然也有因遺傳造成,也常發生於甲狀腺或副甲狀腺手術後,或是免疫系統障礙造成。治療方法有人工荷爾蒙,鈣劑和維他命的給藥等。

本報告提供副甲狀腺功能低下症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

副甲狀腺功能低下症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • 中外製藥
  • Rare Disease Therapeutics, Inc.
  • Shire Plc

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停中的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8685IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H2 2016, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively.Hypoparathyroidism.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypoparathyroidism Overview
  • Therapeutics Development
    • Pipeline Products for Hypoparathyroidism - Overview
  • Hypoparathyroidism - Therapeutics under Development by Companies
  • Hypoparathyroidism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hypoparathyroidism - Products under Development by Companies
  • Hypoparathyroidism - Companies Involved in Therapeutics Development
    • Ascendis Pharma A/S
    • Chugai Pharmaceutical Co Ltd
    • Eli Lilly and Company
    • Shire Plc
  • Hypoparathyroidism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Eu-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • parathyroid hormone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PCO-371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTH-RM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Agonize Parathyroid Hormone Receptor for Hypoparathyroidism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypoparathyroidism - Dormant Projects
  • Hypoparathyroidism - Product Development Milestones
    • Featured News & Press Releases
      • Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism
      • Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA)) in Hypoparathyroidism
      • Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015
      • Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism
      • Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application
      • Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara for Hypoparathyroidism
      • Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism
      • Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12 - PDUFA Date of October 24 Remains Unchanged
      • Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism
      • Jan 03, 2014: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara in Europe
      • Oct 24, 2013: NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara in Hypoparathyroidism
      • Oct 07, 2013: Natpara Pivotal Study Published in The Lancet Diabetes & Endocrinology
      • Oct 07, 2013: New Findings from the REPLACE Study Suggest Natpara Has a Beneficial Effect on Bone Health in Patients with Hypoparathyroidism
      • Jun 17, 2013: NPS Pharma To Present Data On Natpara As Parathyroid Hormone Replacement Therapy In Patients With Hypoparathyroidism At ENDO 2013
      • Jun 05, 2013: NPS Pharma Announces Presentation Of Data From Natpara REPLACE Study And PARADOX Study At ENDO 2013
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypoparathyroidism, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H2 2016
  • Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Hypoparathyroidism - Pipeline by Eli Lilly and Company, H2 2016
  • Hypoparathyroidism - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypoparathyroidism - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hypoparathyroidism, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top